Caseware UK (AP4) 2024.0.164 2024.0.164 2023-04-01falseNo description of principal activity22truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false NI606208 2023-04-01 2024-03-31 NI606208 2022-04-01 2023-03-31 NI606208 2024-03-31 NI606208 2023-03-31 NI606208 c:Director1 2023-04-01 2024-03-31 NI606208 d:OtherPropertyPlantEquipment 2023-04-01 2024-03-31 NI606208 d:OtherPropertyPlantEquipment 2024-03-31 NI606208 d:OtherPropertyPlantEquipment 2023-03-31 NI606208 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 NI606208 d:CurrentFinancialInstruments 2024-03-31 NI606208 d:CurrentFinancialInstruments 2023-03-31 NI606208 d:Non-currentFinancialInstruments 2024-03-31 NI606208 d:Non-currentFinancialInstruments 2023-03-31 NI606208 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 NI606208 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 NI606208 d:Non-currentFinancialInstruments d:AfterOneYear 2024-03-31 NI606208 d:Non-currentFinancialInstruments d:AfterOneYear 2023-03-31 NI606208 d:ShareCapital 2024-03-31 NI606208 d:ShareCapital 2023-03-31 NI606208 d:RetainedEarningsAccumulatedLosses 2024-03-31 NI606208 d:RetainedEarningsAccumulatedLosses 2023-03-31 NI606208 c:OrdinaryShareClass1 2023-04-01 2024-03-31 NI606208 c:OrdinaryShareClass1 2024-03-31 NI606208 c:OrdinaryShareClass1 2023-03-31 NI606208 c:FRS102 2023-04-01 2024-03-31 NI606208 c:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 NI606208 c:FullAccounts 2023-04-01 2024-03-31 NI606208 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 NI606208 e:PoundSterling 2023-04-01 2024-03-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: NI606208










M&J Clinical Associates Ltd








Unaudited

Financial statements

Information for filing with the registrar

For the Year Ended 31 March 2024

 
M&J Clinical Associates Ltd
Registered number:NI606208

Balance Sheet
As at 31 March 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 5 
428
907

  
428
907

Current assets
  

Debtors: amounts falling due within one year
 6 
1,116
116

Cash at bank and in hand
 7 
43,114
29,634

  
44,230
29,750

Creditors: amounts falling due within one year
 8 
(22,944)
(23,070)

Net current assets
  
 
 
21,286
 
 
6,680

Total assets less current liabilities
  
21,714
7,587

Creditors: amounts falling due after more than one year
 9 
(3,269)
(5,849)

  

Net assets
  
18,445
1,738


Capital and reserves
  

Called up share capital 
 10 
2
2

Profit and loss account
  
18,443
1,736

  
18,445
1,738


img71c7.png
Page 1

 
M&J Clinical Associates Ltd
Registered number:NI606208

Balance Sheet (continued)
As at 31 March 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 31 January 2025.




Dr Modestas Jarutis
Director

The notes on pages 3 to 7 form part of these financial statements.

img2057.png
Page 2

 
M&J Clinical Associates Ltd
 
 
Notes to the Financial Statements
For the Year Ended 31 March 2024

1.


General information

M&J Clinical Associates Ltd is a private company limited by shares incorporated in Northern Ireland. The registration number and address of the registered office are given in the company information section of these financial statements.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

img437d.png
Page 3

 
M&J Clinical Associates Ltd
 

Notes to the Financial Statements
For the Year Ended 31 March 2024

2.Accounting policies (continued)

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.6

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Income and Retained Earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

 
2.7

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.8

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.9

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


img1dba.png
Page 4

 
M&J Clinical Associates Ltd
 

Notes to the Financial Statements
For the Year Ended 31 March 2024

2.Accounting policies (continued)

 
2.10

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Equipment
-
20%
Straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.


3.


Going Concern

The Directors of M&J Clinical Associates Ltd have reviewed the resources available and believe that the company has adequate resources to continue in operational existence for the foreseeable future.
The Directors have considered the financial position at the year end and believe that the Company will have sufficient resources to meet its liabilities as they fall due either from its own resources or ongoing support from directors for at least one year from the date of approval of these financial statements.
Accordingly, M&J Clinical Associates Ltd continues to adopt the going concern basis in preparing the financial statements.


4.


Employees

The average monthly number of employees, including directors, during the year was 2 (2023 - 2)

img136c.png
Page 5

 
M&J Clinical Associates Ltd
 
 
Notes to the Financial Statements
For the Year Ended 31 March 2024

5.


Tangible fixed assets





Equipment

£



Cost or valuation


At 1 April 2023
6,724



At 31 March 2024

6,724



Depreciation


At 1 April 2023
5,817


Charge for the year on owned assets
479



At 31 March 2024

6,296



Net book value



At 31 March 2024
428



At 31 March 2023
907


6.


Debtors: amounts falling due within one year

2024
2023
£
£


Other debtors
-
116

Prepayments and accrued income
1,116
-



7.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
43,114
29,634


img76cb.png
Page 6

 
M&J Clinical Associates Ltd
 
 
Notes to the Financial Statements
For the Year Ended 31 March 2024

8.


Creditors: amounts falling due within one year

2024
2023
£
£

Bank loans
2,768
2,768

Corporation tax
4
4

Other creditors
16,872
14,948

Accruals and deferred income
3,300
5,350

22,944
23,070



9.


Creditors: amounts falling due after more than one year

2024
2023
£
£

Bank loans
3,269
5,849



10.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



2 (2023 - 2) Ordinary shares of £1.00 each
2
2



img4a3c.png
Page 7